Chinese clinical stage biotech company Hua Medicine has reported positive results from its Phase II monotherapy trial of HMS5552 to treat diabetes.

HMS5552 is the company’s fourth-generation glucokinase activator, which targets one of the important enzymes posing as a glucose sensor and controlling the pathways for carbohydrate metabolism.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The Phase II monotherapy trial was undertaken as a multicentre, randomised, double-blind, placebo-controlled, parallel five-dose arm study, which involved 258 Type 2 Diabetes patients.

The patients were administered with HMS5552 and placebo over a period of 12 weeks, following a standardised four-week placebo run-in period.

"Results suggested the efficacy of HMS5552 in addressing diabetes, while exhibiting tolerability and safety profile with low risk of hypoglycemia or other associated side effects."

Results suggested the efficacy of HMS5552 in addressing diabetes, while exhibiting tolerability and safety profile with low risk of hypoglycemia or other associated side effects.

Hua Medicine clinical research and development vice-president Dr Yi Zhang said: "We are very thankful for the incredible effort put forth by Hua's operational team, CRO and SMO partners, our physician collaborators at all 22 hospital centres, and all of our participating diabetes patients who made this trial possible.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"The excellent results of our clinical studies are a testament to our team's adherence to the highest international standards of quality control that always places patient health and safety as primary goals."

According to Hua Medicine CEO Dr Li Chen, subject to regulatory authority approvals, the company is planning to begin the Phase III pivotal studies of HMS5552 next year.